Acid-Stable Prolyl Endopeptidase Oral Enzyme Therapy for Gluten Degradation
Formulation and development of recombinant and natural acid-stable prolyl endopeptidases (such as Aspergillus niger prolyl endoprotease, AN-PEP) that remain enzymatically active at gastric pH (2.0 to 4.0), cleaving internal immunogenic proline- and glutamine-rich peptides (e.g. 33-mer) in gluten before they transit into the duodenum, protecting individuals with non-celiac gluten sensitivity.
1 · What it gives
Acid-stable prolyl endopeptidase (AN-PEP) oral enzyme therapy represents a pioneering biotherapeutic intervention designed to degrade immunogenic gluten peptides directly within the human gastric environment, mitigating cross-contamination risks for individuals suffering from non-celiac gluten sensitivity (NCGS) and celiac disease. Dietary gluten—a composite storage protein found in wheat, rye, and barley—is rich in the amino acids proline (~15%) and glutamine (~35%). Endogenous human gastric and pancreatic proteases (pepsin, trypsin, chymotrypsin) are biochemically incapable of cleaving peptide bonds adjacent to rigid, cyclic proline residues. Consequently, resistant, highly immunogenic oligopeptides—exemplified by the toxic alpha-gliadin 33-mer fragment—reach the duodenum intact, where they trigger tight-junction barrier breakdown, zonulin release, and severe inflammatory HLA-DQ2/DQ8-restricted T-cell immune responses.
The industrial and clinical benchmark enzyme, Aspergillus niger prolyl endopeptidase (AN-PEP; commercialized as Tolerase® G by DSM-Firmenich), is a specialized recombinant post-proline cleaving serine endoprotease. Unlike standard neutral prolyl oligopeptidases that are instantly irreversibly inactivated by stomach acid, AN-PEP possesses an acidic pH optimum of 4.0–4.5 and retains full catalytic activity across pH 2.0 to 5.5, remaining completely resistant to degradation by gastric pepsin. Clinical in vivo human intragastric cannulation studies establish that co-ingestion of AN-PEP with a gluten-containing meal hydrolyzes over 90% of immunogenic gluten peptides in the stomach within 60–90 minutes, cleaving intact 33-mer sequences into non-immunogenic di- and tripeptides before the chyme empties through the pylorus into the small intestine.
The key directions of this technology are:
- Acid-Resistant Serine Endopeptidase Engineering: Recombinant expression and structural stabilization of Aspergillus niger post-proline cleaving endoproteases retaining extreme low-pH and pepsin tolerance.
- High-Density Fungal Fermentation & Downstream Refining: Industrial submerged fermentation of food-grade Aspergillus niger production chassis achieving high enzymatic yields (>50,000 PPU/g) with zero mycotoxin contamination.
- Gastro-Retentive Oral Formulation: Formulating enteric micro-granules or rapid-dissolving capsules that disperse instantaneously in gastric fluid (t < 5 minutes) to digest hidden dietary gluten before gastric emptying.
- Clinical Immunogenicity Profiling & Celiac Adjuvants: Evaluating mucosal protection in double-blind challenge trials to validate complete destruction of immunodominant T-cell epitopes.
Sectoral value chain#
[Aspergillus niger Fermentation] ──> [Continuous Microfiltration & Clarification] ──> [Ultrafiltration Concentration]
│
(Sterile Polish & Ultra-Pure Spray Drying)
│
▼
[Enteric Gastric Enzyme Capsules] <─── [Pellet Fluid-Bed Coating & Packaging] <───────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Fungal Inoculum & Media Preparation | Inoculating certified Aspergillus niger production strains into refined beet molasses or dextrose broth optimized for extracellular enzyme secretion. | In: Fungal master spore stock, carbohydrates, nitrogen. Out: Sterile fungal seed broth with high germination (>99%). |
| Submerged Aerobic Fermentation | Industrial scale submerged fermentation in 50,000L to 100,000L stirred bioreactors with automated aeration, pH control, and carbon feeding. | In: Seed inoculum, sterile air, mineral nutrients. Out: Enzyme-rich fermentation broth with extracellular AN-PEP titers. |
| Centrifugal & Depth Microfiltration | Continuous clarification via disk-stack centrifuges and multi-layer depth filter pads to eliminate fungal hyphae and cell debris. | In: Crude fermentation broth, food-grade filter aid (diatomaceous earth). Out: Clarified, cell-free enzyme filtrate (>90% recovery). |
| Ultrafiltration & Buffer Exchange | Continuous tangential flow filtration across 10 kDa polyethersulfone membranes, concentrating enzyme volume by 10-fold while washing mineral salts. | In: Cell-free filtrate, demineralized water. Out: Concentrated, desalted liquid enzyme bulk substance. |
| Aseptic Spray Drying & Fluidized Bed | Low-temperature spray drying with food-grade maltodextrin carriers under controlled chamber temperatures (<60°C product temp) to preserve activity. | In: Enzyme concentrate, non-GMO maltodextrin. Out: Free-flowing, dry enzyme powder (>50,000 PPU/g activity). |
| Gastric Micro-Pellet Coating & Encapsulation | Fluidized bed Wurster coating of sugar cores with enzyme layers, filled into targeted fast-release vegetarian capsules. | In: Enzyme powder, neutral pellets, HPMC capsules. Out: Finished, shelf-stable oral enzyme dietary supplement. |
Cross-cutting technologies of the sector:
- Protease Proline Cleavage Unit (PPU) Fluorometric Assay: Standardized analytical activity assay measuring hydrolysis rate of synthetic substrate Z-Gly-Pro-pNA at pH 4.5.
- R5 / G12 Monoclonal Sandwich ELISA Assays: Quantification of residual gluten peptides below the Codex Alimentarius limit (<20 ppm) in digested food matrices.
- Dynamic In Vitro Gastric Digestion Models (TIM-1 / SHIME): Computer-controlled simulated human gastric and duodenal reactors verifying gluten degradation kinetics under physiological gastric emptying rates.
2 · What it replaces 6 · matched by industry
| D3E– | Citric acid by Aspergillus niger fermentation instead of extraction from citrus fruit Replaces: Citric acid extracted from lemons, limes and other citrus (calcium citrate route, Italy and California before 1930) | FOOD |
| D3E2 | Glutamate and MSG by bacterial fermentation instead of protein hydrolysis and chemical synthesis Replaces: Hydrolysis of wheat gluten or soybean protein with hydrochloric acid (1909–1960s); acrylonitrile-based chemical synthesis (Japan, … | FOOD |
| D3E– | Fermentation-produced chymosin instead of calf rennet in cheesemaking Replaces: Natural calf rennet (abomasum extract from veal calves); part of microbial/mold coagulants where bitterness was the problem | FOOD |
| D1E2 | Natural antioxidants — tocopherols, rosemary extract, ascorbyl palmitate — instead of BHA and BHT Replaces: Synthetic phenolic antioxidants BHA (E320) and BHT (E321) in fats, oils, snacks, cereals, meat and fish products; part of synthetic … | FOOD |
| D1E– | Baking enzymes (fungal amylase, maltogenic amylase, xylanase, glucose oxidase, lipase) plus ascorbic acid instead of potassium bromate and azodicarbonamide as flour treatment agents Replaces: Potassium bromate (KBrO₃) and azodicarbonamide (ADA) used as oxidizing flour improvers/dough conditioners; part of chemical emulsifier use … | FOOD |
| D2E– | Enzymatic degumming (phospholipases) and enzymatic interesterification (immobilized lipases) of edible oils instead of acid–caustic chemical degumming and sodium-methoxide chemical interesterification Replaces: Phosphoric/citric acid plus caustic soda degumming and neutralization (soapstock, wastewater, oil losses); chemical interesterification with … | FOOD |
3 · How to implement 4 steps
- 1High-expression microbial fermentation of AN-PEPCulturing engineered Aspergillus niger strains in fed-batch fermenters to secrete large amounts of stable prolyl endoprotease.
- 2Low-pH kinetic validation and peptide cleavage analysisAssaying enzyme catalytic rate against synthetic chromogenic substrates and whole gluten digests at pH 2.5 to 4.5.
- 3HPLC-MS/MS 33-mer immunogenic epitope degradation testingDemonstrating total cleavage of toxic celiac-reactive gluten peptides into harmless di- and tripeptides within 30 minutes.
- 4Gastric-release fast-acting chewable tablet formulationFormulating micro-granulated enzyme with buffering excipients for immediate dissolution and action during meals.
4 · Who delivers
Matched suppliers (matched automatically)
| Tianguan Group | China | Producer | active |
| Vezlay Foods | India | Producer | active |
| PH-Albio | Spain | Producer | active |
| BENEXIA® | Chile | Producer | active |
| Isomerase | United Kingdom | Producer | active |
| Jindan Lactic Acid 金丹科技 (SZ 300829) | China | Producer | active |
| BRAIN Biotech | Germany | Producer | active |
| Algalif | Iceland | Producer | active |
| Feed Concentrate Factory Company (FEEDCO) | Jordan | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| DSM-Firmenich | 🇨🇭 Switzerland / 🇳🇱 Netherlands | Tolerase® G (AN-PEP) | Global pioneer and patent holder of acid-stable Aspergillus niger prolyl endopeptidase for gluten breakdown | commercial |
| Bioventus | 🇺🇸 USA | Oral Enzyme Therapeutics | Clinical biopharmaceutical company advancing investigational digestive enzyme candidates for gastrointestinal disorders | clinical |
| Amano Enzyme | 🇯🇵 Japan | Specialty Industrial Proteases | Leading Japanese microbial enzyme manufacturer producing specialized endopeptidases and peptidases | commercial |
| Kerry Group | 🇮🇪 Ireland | Digestive Health Enzymes | Global taste and nutrition leader formulating digestive enzymes and microbiome solutions for functional foods | commercial |
| Nemysis | 🇮🇪 Ireland | E40 Glutenase Platform | Biopharmaceutical company developing targeted enzymatic countermeasures against gluten toxicity | clinical |
| Novonesis (Novozymes) | 🇩🇰 Denmark | Bio-Industrial Enzymes | Global industrial biosolutions powerhouse with deep technical expertise in fungal enzyme expression | commercial |
| ImmunoGenX | 🇺🇸 USA | Latiglutenase (ALV003) | Clinical developer of targeted dual-enzyme therapy (cysteine protease and prolyl endopeptidase) for celiac disease | clinical |
5 · Rules & route to market
declaration of conformity, or SGR within 30 calendar days for new/specialized ingredients (plus tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
FDA Dietary Supplement Clearances, Celiac Non-Profit Coalitions, and Clinical Trials#
- FDA Dietary Supplement Health and Education Act (DSHEA): Marketed as specialized enzyme dietary supplements supporting gluten digestion and gastrointestinal comfort.
- Celiac Disease Foundation Partnerships: Major clinical foundations evaluating oral enzyme therapy as an essential risk-mitigation shield against accidental dining-out cross-contamination.
- Phase 2 Investigational Drug Pipelines: Bioventus and First Wave Bio advancing recombinant endopeptidases through clinical IND trials as prescription medical countermeasures.
European Union
Swiss / Dutch Biopharma Innovation (DSM-Firmenich / Tolerase G), EFSA, and Coeliac Societies#
- DSM-Firmenich Tolerase® G Benchmark: Global intellectual property and industrial enzyme production hub (Kaiseraugst/Delft) driving world standards in AN-PEP enzyme efficacy.
- European Coeliac Societies Verification: Active clinical trials and endorsements across European coeliac associations supporting oral enzyme supplements.
- EFSA Novel Food & Enzyme Evaluation: European Food Safety Authority positive scientific assessment confirming Aspergillus niger safe strain lineage and zero mycotoxin risk.
China
14th Five-Year Enzyme Engineering, Grain Processing, and Food Safety Standards#
- National Enzyme Industry Modernization: Inclusion of specialized therapeutic and dietary enzymes in national industrial biotechnology upgrade programs.
- Wheat Gluten Food Processing Innovation: Research across major food science universities (Jiangnan University) deploying prolyl endopeptidases to produce hypoallergenic gluten-free wheat flours.
- Growing Urban Digestive Health Market: Rapidly expanding domestic demand for digestive enzyme aids across Tier-1 metropolitan consumer health channels.
6 · Money: tenders & grants
7 · Tech stack & innovations
- Acidic Catalytic Triad Architecture:
- AN-PEP serine protease operates via a unique catalytic triad (Ser-Asp-His) adapted to acidic microenvironments.
- Maintains maximal enzymatic turnover at pH 4.0–4.5, retaining >80% maximal velocity at pH 2.5.
- Inherent structural resistance to pepsin degradation ensures survival in the active gastric juice matrix.
- Submerged Fungal Bioreactor Titers:
- Fed-batch culture of genetically optimized Aspergillus niger strains with non-detectable ochratoxin A or aflatoxin gene clusters.
- Enzyme secretion driven by glucoamylase promoter systems yielding extracellular protein titers >15 g/L.
- Continuous automated dissolved oxygen control (>25%) and temperature maintenance at 30.0°C.
- Rapid-Dissolution Micro-Pellet Kinetics:
- Multi-particulate micro-granules engineered with effervescent or super-disintegrant cores (croscarmellose sodium).
- Complete dissolution and enzyme release occurs in simulated gastric fluid (SGF) in <180 seconds.
- Ensures instantaneous mixing with masticated food boluses during the early stages of a meal before gastric emptying.
Sources 1 · 0 independent · 1 producer sites
Producers' own sites 1
- www.swissbiotech.org producer checked 2026-11-22